Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Nicholas D. Brownstone; Quinn G. Thibodeaux; Vidhatha D. Reddy; Bridget A. Myers; Stephanie Y. Chan; Tina Bhutani; Wilson Liao

doi:10.1007/s13555-020-00394-8

Dermatology and Therapy (May 2020)

Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Nicholas D. Brownstone,
Quinn G. Thibodeaux,
Vidhatha D. Reddy,
Bridget A. Myers,
Stephanie Y. Chan,
Tina Bhutani,
Wilson Liao

Affiliations

Nicholas D. Brownstone: Department of Dermatology, Psoriasis and Skin Treatment Center, University of California, San Francisco
Quinn G. Thibodeaux: Department of Dermatology, Psoriasis and Skin Treatment Center, University of California, San Francisco
Vidhatha D. Reddy: Department of Dermatology, Psoriasis and Skin Treatment Center, University of California, San Francisco
Bridget A. Myers: Department of Dermatology, Psoriasis and Skin Treatment Center, University of California, San Francisco
Stephanie Y. Chan: Department of Dermatology, Psoriasis and Skin Treatment Center, University of California, San Francisco
Tina Bhutani: Department of Dermatology, Psoriasis and Skin Treatment Center, University of California, San Francisco
Wilson Liao: Department of Dermatology, Psoriasis and Skin Treatment Center, University of California, San Francisco

DOI: https://doi.org/10.1007/s13555-020-00394-8
Journal volume & issue: Vol. 10, no. 4
pp. 881 – 885

Abstract

Read online

Abstract The outbreak of the novel coronavirus known as SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) causing COVID-19 was first reported in late December 2019. Many patients with psoriasis on biologic therapy have asked their medical providers about the effect of biologics on COVID-19. However, it is currently unknown how biologic therapy for psoriasis might impact patients with psoriasis and COVID-19. In this article, we report on the clinical course of two patients on biologic medication for psoriasis who developed COVID-19 and successfully recovered from SARS-CoV-2 infection. Both patients presented with fever and respiratory symptoms, but neither patient required hospitalization. While more research is needed, it is reassuring to know that successful recovery is possible after COVID-19 infection in patients on biologic therapy for psoriasis.

Published in Dermatology and Therapy

ISSN: 2193-8210 (Print); 2190-9172 (Online)
Publisher: Adis, Springer Healthcare
Country of publisher: United Kingdom
LCC subjects: Medicine: Dermatology
Website: https://www.springer.com/journal/13555

About the journal

Abstract

Keywords